Effects of Mianserin on Human Sleep

Maeda, Yuji; Hayashi, Takuo; Furuta, Hiroaki; Kim, Y.; Morikawa, Kazuhiro; Ishiguro, Nozomi; Ueno, K.; Sano, Junko; Yamaguchi, Nobuharu

doi:10.1159/000119485

Cited by 12 publications

(11 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The literature search yielded 41 articles published since 1977. Twenty-four articles could be used (Nakazawa et al, 1977;Fernandez-Guardiola et al, 1978;Gnirss, 1986;Nicholson et al, 1986aNicholson et al, ,b, 1988Nicholson et al, , 1989Hopes, 1989;Maeda et al, 1990;Riemann et al, 1990;Ruigt et al, 1990;Kajimura et al, 1991;Saletu et al, 1991;Feuillade et al, 1992;Herdman et al, 1993;Vasar et al, 1994;Ware et al, 1994;Sharpley et al, 1996;Salin-Pascual et al, 1997;Schlosser et al, 1998;Vogal et al, 1998;Yamadera et al, 1998;Jobert et al, 1999;Wilson et al, 2000), because some collected articles were reviews, investigated REM sleep effects in only depressive patients or effects of other drugs (Vogel, 1975;Pavel et al, 1981;Paiva et al, 1988;Wiegand et al, 1989;Blois et al, 1990;Sharpley et al, 1990;Riemann et al, 1992;Armitage et al, 1994;Jarrett et al, 1994;Pasternak et al, 1994;Rotenberg, 1994;Landolt et al, 2001;Scharf et al, 1999;Sharpley et al, 1994;van Bemmel, 1997;Sharpley et al...…”

Section: Resultsmentioning

confidence: 99%

“…The antidepressants are presented in order of decreasing acute effect on REM sleep. The REM sleep effects plotted against the serotonin, noradrenaline and dopamine transporter affinities and muscarinic receptor affinities did not (Riemann et al, 1990) 60.9 67.2 44.8 122.7 Clomipramine (50 mg) (Maeda et al, 1990) 70.3 80.7 80.7 266.3 Dexnafenodone (20 mg) (Jobert et al, 1999) 55.5 64.3 --Dothiepin (100 mg) (Wilson et al, 2000) 16.0 NS 19.3 NS -NS -Fluoxetine (20 mg) (Nicholson et al, 1988) 9.3 NS 9.0 NS 9 NS -17.0 NS Fluoxetine (40 mg) (Nicholson et al, 1988) 3.2 NS 3.1 NS 1.5 NS -1.8 NS Fluoxetine (60 mg) (Nicholson et al, 1988) 45.9 44.4 14.8 8.4 NS Fluoxetine (60 mg) (Nicholson et al, 1989) (Sharpley et al, 1996) 39.0 37.5 37.5 140.0 Paroxetine (20 mg) (Saletu et al, 1991) 26.6 34.1 34.1 102.8 Paroxetine (30 mg) (Saletu et al, 1991) 34.6 44.3 29.5 105.5 Paroxetine (40 mg) (Saletu et al, 1991) 42.9 54.9 27.5 93.2 Trazodone (100 mg) (Ware et al, 1994) 12.33 13.6 20.5 86.7 Trazodone (100 mg) (Yamadera et al, 1998) -10 -8.9 -13.4 14.6 Trimipramine (25 mg) (Nicholson et al, 1989) 13.6 NS 11.7 NS 11.7 NS -0.4 NS Trimipramine (50 mg) (Nicholson et al, 1989) 28 24.1 12.1 13.9 NS Trimipramine (75 mg) (Nicholson et al, 1989) 25.1 21.6 7.2 11.3 NS Trimipramine (100 mg) (Feuillade et al, 1992) show any consistent relationship with the REM sleep effects at therapeutic dose. Serotonin/noradrenaline selectivity ratios were used to examine relationships with serotonergic selectivity, rather than absolute affinity.…”

Section: Single Dosementioning

confidence: 98%

“…For 10 antidepressants, two or more dose levels were investigated (Nakazawa et al, 1977;Nicholson et al, 1986aNicholson et al, ,b, 1988Nicholson et al, , 1989Maeda et al, 1990;Riemann et al, 1990;Saletu et al, 1991;Feuillade et al, 1992;Sharpley et al, 1996;Yamadera et al, 1998;Jobert et al, 1999). As doses increased, nine antidepressants showed greater reductions in REM sleep, with the exception of trimipramine.…”

Section: Single Dosementioning

confidence: 99%

See 2 more Smart Citations

REM Sleep Effects as a Biomarker for the Effects of Antidepressants in Healthy Volunteers

Rijnbeek

Visser²,

Franson³

et al. 2003

J Psychopharmacol

View full text Add to dashboard Cite

The potential use of rapid eye movement (REM) sleep effects as a biomarker for the therapeutic effects of antidepressants in healthy volunteers is reviewed. A literature search was performed to select studies investigating the effects of antidepressants on REM sleep. To assess the specificity of REM sleep effects as a biomarker, the effects of other central nervous system drugs on REM sleep were also investigated. A significant REM sleep reduction was shown for 16 of 21 investigated antidepressants after single-dose (mean reduction 34.1%) and for 11/13 drugs after multiple-dose administration (mean reduction 29.2%). The median increase in REM latency was approximatety 60% after single- or multiple-dose administration. REM sleep effects were linearly normalized to therapeutic doses, by dividing the REM sleep effect by the investigated dose and multiplying by the therapeutic dose. Normalized REM sleep effects were highly variable (range -27.0% to 81.8% for REM sleep; range -17.0% to 266.3% for REM latency) and demonstrated no relationship with relevant pharmacological properties of the investigated drugs. No quantifiable dose-response relationship could be constructed after single and multiple dose administration. REM sleep effects were not specific for antidepressants. Benzodiazepines, for example, caused an average dose normalized REM sleep reduction of 8.7% and a median 8.6% increase of REM latency. This review demonstrates that although REM sleep effects occur with most of the antidepressants, it is by itself of limited value as a biomarker for antidepressant action. The specificity for antidepressants is limited, and it does not show a quantitative dose-response relationship to antidepressant agents. This is at least partly due to the complex relationships between drug pharmacokinetics and the variable time course of REM and other sleep stages throughout the night. Models that take these complex relationships into account may provide more comprehensive and quantifiable results.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Single Dosementioning

confidence: 98%

Section: Single Dosementioning

confidence: 99%

See 1 more Smart Citation

REM Sleep Effects as a Biomarker for the Effects of Antidepressants in Healthy Volunteers

Rijnbeek

Visser²,

Franson³

et al. 2003

J Psychopharmacol

View full text Add to dashboard Cite

show abstract

“…Mianserin, a tetracyclic and atypical antidepressant, has an antagonistic effect on 5-HT 2A/C , 5-HT 3 , H 1 , α1 and α2-adrenergic receptors. It is commonly used for the management of depression and anxiety disorders especially the patients or healthy groups which have the impaired sleep quality [1][2][3].…”

Section: Introductionmentioning

confidence: 99%

“…It is commonly used for the management of depression and anxiety disorders especially the patients or healthy groups which have the impaired sleep quality [1][2][3]. Mianserin is generally a safe and well-tolerated medication choice compared with the other antidepressant groups [4].…”

Section: Introductionmentioning

confidence: 99%

Mianserin induced periorbital edema: a case report

Gündoğmuş

İspir

Algül

2017

Psychiatry and Clinical Psychopharmacology

View full text Add to dashboard Cite

Objectives:The rare side effects as periorbital edema are worth to discuss most of the times. Periorbital edema is a rare and serious allergic condition. The etiology of this situation might be seen in different status that they are commonly independent of each other's as well as their various speculated formation mechanisms. The drug induced side effects might be seen in the etiologic factors basket of periorbital edema. Methods: Observational case report. Results: The authors describe a 30-year-old woman with generalized anxiety disorder who developed periorbital edema while undergoing of treatment with mianserin. Conclusions: Interestingly, we observed a relationship with periorbital edema and a safe, effective, well-tolerated atypical antidepressant-mianserin. This is the first-demonstrated case in literature periorbital edema due to mianserin. The case is enormous importance for contributing the side effect set of periorbital edema. Thus, it will be useful contribution for the daily practice of physicians and the other professions.ARTICLE HISTORY

show abstract

Antidepressants and their effect on sleep

Mayers

Baldwin

2005

Human Psychopharmacology

277

180

View full text Add to dashboard Cite

Given the relationship between sleep and depression, there is inevitably going to be an effect of antidepressants on sleep. Current evidence suggests that this effect depends on the class of antidepressant used and the dosage. The extent of variation between the effects of antidepressants and sleep may relate to their mechanism of action. This systematic review examines randomised-controlled trials (RCTs) that have reported the effect that antidepressants appear to have on sleep. RCTs are not restricted to depressed populations, since several studies provide useful information about the effects on sleep in other groups. Nevertheless, the distinction is made between those studies because the participant's health may influence the baseline sleep profiles and the effect of the antidepressant. Insomnia is often seen with monoamine oxidase inhibitors (MAOIs), with all tricyclic antidepressants (TCAs) except amitriptyline, and all selective serotonin reuptake inhibitors (SSRIs) with venlafaxine and moclobemide as well. Sedation has been reported with all TCAs except desipramine, with mirtazapine and nefazodone, the TCA-related maprotiline, trazodone and mianserin, and with all MAOIs. REM sleep suppression has been observed with all TCAs except trimipramine, but especially clomipramine, with all MAOIs and SSRIs and with venlafaxine, trazodone and bupropion. However, the effect on sleep varies between compounds within antidepressant classes, differences relating to the amount of sedative or alerting (insomnia) effects, changes to baseline sleep parameters, differences relating to REM sleep, and the degree of sleep-related side effects.

show abstract

Effects of Mianserin on Human Sleep

Cited by 12 publications

References 10 publications

REM Sleep Effects as a Biomarker for the Effects of Antidepressants in Healthy Volunteers

REM Sleep Effects as a Biomarker for the Effects of Antidepressants in Healthy Volunteers

Mianserin induced periorbital edema: a case report

Antidepressants and their effect on sleep

Contact Info

Product

Resources

About